16
Participants
Start Date
December 16, 2021
Primary Completion Date
October 4, 2022
Study Completion Date
October 4, 2022
Screening Platform
Eligible participants who qualify as per this screening protocol may be referred to evaluate adoptive cell therapy in participants with various malignancies, on a separate treatment trial. No study treatment will be administered in this screening study.
GSK Investigational Site, Gainesville
GSK Investigational Site, Waterloo
GSK Investigational Site, Springfield
Lead Sponsor
GlaxoSmithKline
INDUSTRY